18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

about

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

Item

http://www.wikidata.org/entity/Q55456352

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@en

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@nl

type

Item

label

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@en

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@nl

prefLabel

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@en

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model.

@nl

P1476

18F-fluoromisonidazole predicts evofosfamide uptake in pancreatic tumor model

@en

P2093

John L Humm

http://www.w3.org/2001/XMLSchema#string

Louise Fanchon

http://www.w3.org/2001/XMLSchema#string

Naga Vara Kishore Pillarsetty

http://www.w3.org/2001/XMLSchema#string

P2860

Immunohistochemical detection of changes in tumor hypoxia

TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Measurement of Tumor Hypoxia in Patients with Advanced Pancreatic Cancer Based on 18F-Fluoroazomyin Arabinoside Uptake.

Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer.

In Vitro and In Vivo Comparison of Gemcitabine and the Gemcitabine Analog 1-(2'-deoxy-2'-fluoroarabinofuranosyl) Cytosine (FAC) in Human Orthotopic and Genetically Modified Mouse Pancreatic Cancer Models.

Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer.

Detection of hypoxia with 18F-fluoromisonidazole (18F-FMISO) PET/CT in suspected or proven pancreatic cancer.

Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation O

P2888

s13550-018-0409-1

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13550-018-0409-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

James Russell

M Grkovski

P577

2018-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1104893162

http://www.w3.org/2001/XMLSchema#string

P698

29916085

http://www.w3.org/2001/XMLSchema#string

P932

6005997

http://www.w3.org/2001/XMLSchema#string